Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUDSON GI Study of benralizumab in eosinophilic gastritis and/or gastroenteritis
2021-000085-14Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic gastritis (EG) and eosinophilic enteritis (EoN) comparing Benralizumab with Placebo (2 arms). Primary endpoint: Dual primary endpoints. Started May 2021; status: completed.
02
Drugs
benralizumab
03
Conditions
eosinophilic gastritis (EG)eosinophilic enteritis (EoN)
Beyond the preview
Go deeper on 2021-000085-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000085-14.